Chiusura precedente | 42,33 |
Aperto | 43,14 |
Denaro | 41,23 x 200 |
Lettera | 41,54 x 100 |
Min-Max giorno | 39,95 - 43,59 |
Intervallo di 52 settimane | 7,10 - 50,78 |
Volume | |
Media Volume | 1.037.412 |
Capitalizzazione | 2,25B |
Beta (5 anni mensile) | 1,11 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -2,25 |
Prossima data utili | 08 ago 2024 - 12 ago 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 48,63 |
Informational poster for ORIGIN 3 Pivotal Phase 3 study evaluating atacicept in IgA Nephropathy (IgAN) Additional analysis of week 36 data from Phase 2b ORIGIN study show atacicept 150mg reduces serum Gd-IgA1, supporting atacicept’s potential as long-term disease-modifying IgAN therapy Atacicept showed continued protective titers to diphtheria and tetanus and balanced COVID infections vs. placebo in IgAN BRISBANE, Calif., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA),
BRISBANE, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present and participate in one-on-one meetings at four investor conferences being held next month. Investor Conference Details: Citi 18th Annual BioPharma ConferenceFormat: Management hostin
Presented positive 36-week results from the Phase 2b ORIGIN clinical trial of atacicept in IgAN as a late breaking clinical trial at the 60th ERA CongressInitiated Phase 3 ORIGIN 3 clinical trial of atacicept in June for the treatment of IgANStrong balance sheet expected to fund operations to early 2026 BRISBANE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative tr